Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
4.280
+0.030 (0.71%)
Aug 17, 2026, 12:34 PM EDT - Market open
Aquestive Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 54.09 | 44.55 | 57.56 | 50.58 | 47.68 | 50.83 | |
Revenue Growth | 22.56% | -22.61% | 13.79% | 6.09% | -6.20% | 10.87% |
Cost of Revenue | 17.83 | 18.56 | 17.87 | 20.83 | 19.39 | 14.99 |
Gross Profit | 36.26 | 25.99 | 39.69 | 29.75 | 28.29 | 35.84 |
Selling, General & Admin | 73.11 | 79.85 | 50.18 | 31.75 | 52.88 | 53.48 |
Research & Development | 15.89 | 17.19 | 20.28 | 13.1 | 17.48 | 17.05 |
Operating Expenses | 89 | 97.04 | 70.46 | 44.85 | 70.36 | 70.52 |
Operating Income | -52.75 | -71.05 | -30.77 | -15.1 | -42.07 | -34.68 |
Interest Expense | -16.32 | -17.1 | -16.82 | -7.46 | -12.44 | -22.46 |
Interest & Investment Income | 2.52 | 4.37 | 3.14 | 1.82 | 0.1 | 0.42 |
Other Non Operating Income (Expenses) | - | - | - | 6 | - | - |
EBT Excluding Unusual Items | -66.54 | -83.78 | -44.45 | -14.74 | -54.41 | -56.72 |
Legal Settlements | - | - | - | 8.5 | - | - |
Other Unusual Items | -11.68 | - | 0.3 | -1.38 | - | -13.82 |
Pretax Income | -78.23 | -83.78 | -44.15 | -7.63 | -54.41 | -70.54 |
Income Tax Expense | - | - | -0.01 | 0.25 | - | - |
Net Income | -78.23 | -83.78 | -44.14 | -7.87 | -54.41 | -70.54 |
Net Income to Common | -78.23 | -83.78 | -44.14 | -7.87 | -54.41 | -70.54 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 120 | 107 | 87 | 61 | 49 | 38 |
Shares Outstanding (Diluted) | 120 | 107 | 87 | 61 | 49 | 38 |
Shares Change | 27.37% | 23.29% | 41.58% | 25.69% | 27.99% | 13.15% |
EPS (Basic) | -0.65 | -0.78 | -0.51 | -0.13 | -1.12 | -1.85 |
EPS (Diluted) | -0.65 | -0.78 | -0.51 | -0.13 | -1.12 | -1.85 |
EPS Growth | - | - | - | - | - | - |
Free Cash Flow | -45.95 | -52.99 | -35.92 | -7.38 | -10.84 | -33.89 |
Free Cash Flow Per Share | -0.38 | -0.50 | -0.41 | -0.12 | -0.22 | -0.89 |
Gross Margin | 67.04% | 58.34% | 68.95% | 58.82% | 59.34% | 70.51% |
Operating Margin | -97.52% | -159.50% | -53.46% | -29.86% | -88.23% | -68.22% |
Profit Margin | -144.63% | -188.09% | -76.68% | -15.56% | -114.12% | -138.77% |
Free Cash Flow Margin | -84.95% | -118.97% | -62.40% | -14.58% | -22.74% | -66.67% |
EBITDA | -52.2 | -70.48 | -30.03 | -13.73 | -39.51 | -31.53 |
EBITDA Margin | -96.51% | -158.22% | -52.17% | -27.14% | -82.87% | -62.02% |
D&A For EBITDA | 0.54 | 0.57 | 0.74 | 1.37 | 2.55 | 3.15 |
EBIT | -52.75 | -71.05 | -30.77 | -15.1 | -42.07 | -34.68 |
EBIT Margin | -97.52% | -159.50% | -53.46% | -29.86% | -88.23% | -68.22% |